Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12228130 | 0.90 | PGR (0.48) | CDK2GSK3AGSK3BROCK1CAMK2B | |
| SCHEMBL19986220 | 0.88 | CDK2 (0.45) | CDK2GSK3AGSK3BROCK1CAMK2B | |
| SCHEMBL31736768 | 0.85 | CDK2 (0.65) | CDK2GSK3AGSK3BROCK1CAMK2B | |
| SCHEMBL22271630 | 0.85 | BRD4 (0.38) | CDK2GSK3AGSK3BROCK1CAMK2B | |
| SCHEMBL22271629 | 0.85 | CHRM1 (0.41) | CDK2GSK3AGSK3BROCK1CAMK2B | |
| SCHEMBL22271442 | 0.81 | BRD4 (0.34) | CDK2GSK3AGSK3BROCK1CAMK2B | |
| SCHEMBL19986218 | 0.80 | CDK2 (0.44) | CDK2GSK3AGSK3BROCK1CAMK2B | |
| SCHEMBL9284742 | 0.78 | RECQL (0.43) | ADORA3CNR1BRD4RECQLTSPO | |
| SCHEMBL9281498 | 0.78 | RECQL (0.38) | CNR1BRD4RECQL | |
| SCHEMBL19986334 | 0.76 | BRD4 (0.40) | ADORA3BRD4TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103694253-A | Preparation method of thieno triazolo [4,3-A][1,4]diazepin compound | Hunan huateng pharmaceutical co ltd | 2014-04-02 | — | — | CN | claimed |
| US-20220185820-A1 | BRD4 INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFOR AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO. LTD. (CN) | 2022-06-16 | — | — | US | disclosed |
| US-11312726-B2 | Thienodiazepine derivatives and application thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-04-26 | — | — | US | disclosed |
| US-20210017190-A1 | THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| WO-2020192637-A1 | BRD4 INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2020-10-01 | — | — | WO | disclosed |
| EP-3686204-A1 | THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| EP-3129378-B1 | BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER | KAINOS MEDICINE INC (KR) | 2019-06-26 | — | — | EP | disclosed |
| CN-103694253-A | Preparation method of thieno triazolo [4,3-A][1,4]diazepin compound | Hunan huateng pharmaceutical co ltd | 2014-04-02 | — | — | CN | disclosed |
| EP-0989131-B1 | THIENOTRIAZOLODIAZEPINE COMPOUNDS AND MEDICINAL USES THEREOF | MITSUBISHI PHARMA CORP (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0989131-A1 | THIENOTRIAZOLODIAZEPINE COMPOUNDS AND MEDICINAL USES THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017190-A1 | THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF | BRD4, BRD3, BRD2 | CDK2 1050/4885GSK3A 603/4885GSK3B 353/4885 |
| US-11312726-B2 | Thienodiazepine derivatives and application thereof | BRD4, BRD3, BRD2 | CDK2 1050/4885GSK3A 603/4885GSK3B 353/4885 |
| US-20220185820-A1 | BRD4 INHIBITOR COMPOUND IN SOLID FORM AND PREPARATION METHOD THEREFOR AND USE THEREOF | BRD4, BICRA, BET1 | CDK2 185/4885GSK3A 1636/4885GSK3B 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.